These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 15463855)
1. Cost of care and clinical condition in paediatric cystic fibrosis patients. Baumann U; Stocklossa C; Greiner W; von der Schulenburg JM; von der Hardt H J Cyst Fibros; 2003 Jun; 2(2):84-90. PubMed ID: 15463855 [TBL] [Abstract][Full Text] [Related]
2. Healthcare expenditures for privately insured people with cystic fibrosis. Ouyang L; Grosse SD; Amendah DD; Schechter MS Pediatr Pulmonol; 2009 Oct; 44(10):989-96. PubMed ID: 19768806 [TBL] [Abstract][Full Text] [Related]
3. Assessing the cost of cystic fibrosis diagnosis and treatment. Rosenberg MA; Farrell PM J Pediatr; 2005 Sep; 147(3 Suppl):S101-5. PubMed ID: 16202771 [TBL] [Abstract][Full Text] [Related]
4. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance. De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350 [TBL] [Abstract][Full Text] [Related]
5. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Emerson J; Rosenfeld M; McNamara S; Ramsey B; Gibson RL Pediatr Pulmonol; 2002 Aug; 34(2):91-100. PubMed ID: 12112774 [TBL] [Abstract][Full Text] [Related]
6. Short-term persistence of high health care costs in a nationally representative sample of children. Liptak GS; Shone LP; Auinger P; Dick AW; Ryan SA; Szilagyi PG Pediatrics; 2006 Oct; 118(4):e1001-9. PubMed ID: 17015496 [TBL] [Abstract][Full Text] [Related]
7. Healthcare utilization and costs of patients with rosacea in an insured population. Romanowicz M; Stephenson JJ; Del Rosso JQ; Lenhart G J Drugs Dermatol; 2008 Jan; 7(1):41-9. PubMed ID: 18246697 [TBL] [Abstract][Full Text] [Related]
8. Cost of home and hospital care for patients with cystic fibrosis followed up in two reference medical centers in France. Horvais V; Touzet S; François S; Bourdy S; Bellon G; Colin C; Durieu I Int J Technol Assess Health Care; 2006; 22(4):525-31. PubMed ID: 16984688 [TBL] [Abstract][Full Text] [Related]
9. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population. Wertz DA; Chang CL; Stephenson JJ; Zhang J; Kuhn RJ J Med Econ; 2011; 14(6):759-68. PubMed ID: 21942462 [TBL] [Abstract][Full Text] [Related]
10. Energetic cost of physical activity in cystic fibrosis children during Pseudomonas aeruginosa pulmonary exacerbation. Béghin L; Gottrand F; Michaud L; Vodougnon H; Wizla-Derambure N; Hankard R; Husson MO; Turck D Clin Nutr; 2005 Feb; 24(1):88-96. PubMed ID: 15681106 [TBL] [Abstract][Full Text] [Related]
11. Improvements in lung function outcomes in children with cystic fibrosis are associated with better nutrition, fewer chronic pseudomonas aeruginosa infections, and dornase alfa use. McPhail GL; Acton JD; Fenchel MC; Amin RS; Seid M J Pediatr; 2008 Dec; 153(6):752-7. PubMed ID: 18760423 [TBL] [Abstract][Full Text] [Related]
12. Costs and quality of life of multiple sclerosis in Switzerland. Kobelt G; Berg J; Lindgren P; Gerfin A; Lutz J Eur J Health Econ; 2006 Sep; 7 Suppl 2():S86-95. PubMed ID: 17310338 [TBL] [Abstract][Full Text] [Related]
13. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience. Hansen CR; Pressler T; Høiby N J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078 [TBL] [Abstract][Full Text] [Related]
14. Evidence on improved outcomes with early diagnosis of cystic fibrosis through neonatal screening: enough is enough! Farrell PM; Lai HJ; Li Z; Kosorok MR; Laxova A; Green CG; Collins J; Hoffman G; Laessig R; Rock MJ; Splaingard ML J Pediatr; 2005 Sep; 147(3 Suppl):S30-6. PubMed ID: 16202779 [TBL] [Abstract][Full Text] [Related]
15. Economic burden of Pseudomonas aeruginosa infection in patients with cystic fibrosis. Sansgiry SS; Joish VN; Boklage S; Goyal RK; Chopra P; Sethi S J Med Econ; 2012; 15(2):219-24. PubMed ID: 22084956 [TBL] [Abstract][Full Text] [Related]
16. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden. Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A; J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995 [TBL] [Abstract][Full Text] [Related]
17. Costs and quality of life in multiple sclerosis in The Netherlands. Kobelt G; Berg J; Lindgren P; Anten B; Ekman M; Jongen PJ; Polman C; Uitdehaag B Eur J Health Econ; 2006 Sep; 7 Suppl 2():S55-64. PubMed ID: 17310343 [TBL] [Abstract][Full Text] [Related]